Similar results were also found in other human malignancies, such as esophageal, hepatocellular and colon cancers and high-grade glioma, in which down-regulated expression of Beclin 1 was frequently observed in more aggressive tumor subgroups and had a worse prognosis [37], [38], [39], [40]. Here, BECN1 is linked to central nervous system cancer.